Incretin Atlas › Trials › Survodutide phase 2 (obesity)
Survodutide phase 2 (obesity)
Survodutide · obesity
Design
- Molecule(s)
- Survodutide
- Population
- obesity
- Phase
- 2
- Participants
- 387
- Duration
- 46 weeks
- Registry
- NCT04667377
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| survodutide 4.8 mg | obesity | 46 | 387 | −18.7 % vs −2.3 % Δ −16.4 pp | −14.9 % vs −2.8 % Δ −12.1 pp | — | 29.0 vs 4.0 | 39.0 vs 40.3 | 64.0 vs 20.0 | 35.0 vs 5.0 | 5.0 vs 7.0 | −8.6 vs −2.5 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (8)
- survodutide 4.8 mg · weight_eff · Results, paragraph 2 and Table 2
to -18-7% (-20-8 to -16-6; survodutide 4-8 mg) when participants were analysed according to the actual treatment
- survodutide 4.8 mg · weight_tp · Results, paragraph 2; Abstract; Table 2
-14-9% (-16-9 to -13-0; survodutide 4-8 mg) versus -2-8% (-4-9 to -0-7) for placebo
- survodutide 4.8 mg · ae_dc · Results, adverse events paragraph and Table 3
4-8 mg, 22 [29%] of 77; 0-6 mg, 15 [20%] of 7; 2-4 mg, 20 [26%] of 78; 3-6 mg, 19 [25%] of 77
- survodutide 4.8 mg · nausea · Table 3
Nausea” 15 (20%) 26 (34%) 51 (65%) 48 (62%) 49 (64%) 174 (56%)
- survodutide 4.8 mg · vomiting · Table 3
Vomiting" 4(5%) 7(9%) 23 (30%) 26 (34%) 27 (35%) 83 27%)
- survodutide 4.8 mg · sae · Table 3
Serioust 5(7%) 10%) 2%) 6 (8%) 4 (5%) 33 (4%)
- survodutide 4.8 mg · sbp · Table 2, planned treatment
Systolic blood 62 “81 -87 -86 25 37 56 62 62
- survodutide 4.8 mg · disc_any · Figure 1 (trial profile)
20 prematurely stopped 22 prematurely stopped 18 prematurelystopped 18 prematurely stopped 22 prematurely stopped
Primary sources
- Boehringer Ingelheim. A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight. ClinicalTrials.gov identifier NCT04667377. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04667377
- le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. PMID: 38330987.
How to cite this page
Medical Adviser's Group. Incretin Atlas: Survodutide phase 2 (obesity). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/survodutide-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.